Concord Medical Services
3 hedge funds and large institutions have $108K invested in Concord Medical Services in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
1% less capital invested
Capital invested by funds: $108K → $108K (-$577)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$7.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$18.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$125 |
CCM Hedge Fund Activity: Q2 2023 in Review
3 of the 6,382 institutional investors tracked by Wall St. Rank reported a position in Concord Medical Services (CCM) for Q2 2023, worth a combined $108K — down 0.53% from $108K a quarter earlier.
Fund positioning in CCM was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $7.38K. The largest seller was Renaissance Technologies, cutting an estimated $18.4K.
- 3 institutional investors held Concord Medical Services (CCM) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $108K of Concord Medical Services stock for Q2 2023, down 0.53% quarter-over-quarter.
- 1 fund opened new Concord Medical Services positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest Concord Medical Services buyer in Q2 2023 was RhumbLine Advisers, an estimated $7.38K added.
- The largest Concord Medical Services seller in Q2 2023 was Renaissance Technologies, an estimated $18.4K sold.
Based on aggregated 13F filings for Q2 2023.